8-K
filed January 13, 2026, 6:59 PM ET
ticker DWTX
CIK 0001818844
other material
confidence high
sentiment positive
materiality 0.75
Dogwood Therapeutics raises $12.5M upfront; potential $14.4M from warrant exercise
Dogwood Therapeutics, Inc.
- Gross proceeds of $12.5M from registered direct offering and concurrent private placement; potential additional $14.4M upon warrant exercise.
- Offering priced at-the-market under Nasdaq rules: $2.85 per unit (share or pre-funded warrant plus Common Stock warrant).
- Warrants exercisable at $3.28 per share, subject to stockholder approval, expire 5.5 years after approval.
- Company terminated Northland at-the-market agreement; only $89,792 raised under that facility.
- Proceeds to advance Halneuron Phase 2b final data readout and pursue strategic opportunities.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Dogwood Therapeutics, Inc. issued unregistered common stock warrants to purchase up to 4,386,037 shares of Common Stock of warrant to a single institutional investor for combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant.
- Security
- warrant
- Shares
- unregistered common stock warrants to purchase up to 4,386,037 shares of Common Stock
- Purchaser
- a single institutional investor
- Consideration
- combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant
Exact text from the filing
purchase up to 4,386,037 shares of Common Stock (the “Common Stock Warrants,” and together with the Pre-funded Warrants, the “Private Warrants”) at a combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant. The combined offering price per Share and accompanying Common Stock Warrant is $2.85. Exercise of the Common Stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Dogwood Therapeutics, Inc. issued unregistered pre-funded warrants to purchase up to 2,047,089 shares of Common Stock of warrant to a single institutional investor for combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant.
- Security
- warrant
- Shares
- unregistered pre-funded warrants to purchase up to 2,047,089 shares of Common Stock
- Purchaser
- a single institutional investor
- Consideration
- combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant
Exact text from the filing
purchase up to 4,386,037 shares of Common Stock (the “Common Stock Warrants,” and together with the Pre-funded Warrants, the “Private Warrants”) at a combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant. The combined offering price per Share and accompanying Common Stock Warrant is $2.85. Exercise of the Common Stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Dogwood Therapeutics, Inc. issued 2,338,948 shares of common stock to a single institutional investor for combined offering price per Share and accompanying Common Stock Warrant is $2.85.
- Security
- common stock
- Shares
- 2,338,948 shares
- Purchaser
- a single institutional investor
- Consideration
- combined offering price per Share and accompanying Common Stock Warrant is $2.85
Exact text from the filing
purchase up to 4,386,037 shares of Common Stock (the “Common Stock Warrants,” and together with the Pre-funded Warrants, the “Private Warrants”) at a combined offering price of $2.8499 per Pre-funded Warrant and accompanying Common Stock Warrant. The combined offering price per Share and accompanying Common Stock Warrant is $2.85. Exercise of the Common Stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Dogwood Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2026-01-11).
- Action
- entry
- Counterparty
- the Investor
- Effective
- 2026-01-11
Exact text from the filing
On January 11, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Dogwood Therapeutics, Inc. entered into Purchase Agreement with a single institutional investor valued at approximately $12.5 million (effective 2026-01-11).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- a single institutional investor
- Value
- approximately $12.5 million
- Effective
- 2026-01-11
Exact text from the filing
On January 11, 2026, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor named therein (the “Investor”) pursuant to which the Company agreed to sell and issue in a registered direct offering (the “Registered Offering”) to the Investor 2,338,948 shares of common stock
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Dogwood Therapeutics, Inc. terminated Equity Distribution Agreement (effective 2026-01-09).
- Action
- termination
- Agreement
- atm program
- Effective
- 2026-01-09
Exact text from the filing
On January 9, 2026, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”) provided notice of its termination, effective January 9, 2026, of the Equity Distribution Agreement, dated November 28, 2025 (the “Northland Agreement")
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Dogwood Therapeutics, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at approximately $12.5 million (effective 2026-01-11).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Maxim Group LLC
- Value
- approximately $12.5 million
- Effective
- 2026-01-11
Exact text from the filing
On January 11, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.